Recently, Food and Drug Administration (FDA) approved the use of vorinostat and romidepsin (HDAC inhibitors); azacitidine and decitabine (DNMT inhibitors) for the treatment of cutaneous T cell lymphoma and myelodysplastic syndrome7, 8, 9. Here, DNMT1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.